Rilpivirine

🧮 Dose calculator

HIV-1 infection (treatment) · Regimen source: FDA Edurant · 2.2

• • Always with other antiretrovirals (unless a complete regimen). FDA Edurant · 2.2
• • With rifabutin: 50 mg daily. 14–<25 kg: Edurant PED (not interchangeable mg-for-mg). FDA Edurant · 2.7FDA Edurant · 2.1

Enter age and weight.

👥 Special populations

• 🤰 PregnancyUse with caution

  Label: Antiretroviral Pregnancy Registry data show no difference from the background birth-defect rate. FDA Edurant · 8.1

  “Available data from the APR show no difference in the overall risk of birth defects for rilpivirine compared with the background rate for major birth defects of 2.7% in the Metropolitan Atlanta Congenital Defects Program (MACDP) reference population.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Edurant · 8.2

  “Risk Summary Based on limited data after oral administration, rilpivirine is present in human breast milk.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Edurant · 8.4

  “The safety and effectiveness of EDURANT and EDURANT PED has been established for the treatment of HIV-1 infection in treatment-naïve pediatric patients 2 years of age and older and weighing at least 14 kg.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Edurant · 8.5

  “In general, caution should be exercised in the administration and monitoring of EDURANT in elderly patients reflecting the greater frequency of decreased renal and hepatic function, and of concomitant disease or other drug therapy.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.